{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:49:49Z","timestamp":1769197789434,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.arteri.2021.02.006","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T08:40:52Z","timestamp":1621068052000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S2","title":["Hipertrigliceridemias secundarias"],"prefix":"10.1016","volume":"33","author":[{"given":"Clara","family":"Vi\u00f1als","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zamb\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Yago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f2nica","family":"Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2021.02.006_bib0165","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.arteri.2021.02.006_bib0170","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0175","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrcardio.2013.140","article-title":"Demystifying the management of hypertriglyceridaemia","volume":"10","author":"Watts","year":"2013","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2021.02.006_bib0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00041433-200202000-00006","article-title":"Carbohydrate-induced hypertriglyceridemia: modifying factors and implications for cardiovascular risk","volume":"13","author":"Hellerstein","year":"2002","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0190","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation."},{"key":"10.1016\/j.arteri.2021.02.006_bib0195","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Introduction and rationale","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2021.02.006_bib0200","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00000441-199012000-00004","article-title":"Severe Hypertriglyceridemia in Diabetic Ketosis","volume":"300","author":"Fulop","year":"1990","journal-title":"Am J Med Sci."},{"key":"10.1016\/j.arteri.2021.02.006_bib0205","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mcna.2012.01.012","article-title":"The Effect of Thyroid Disorders on Lipid Levels and Metabolism","volume":"96","author":"Duntas","year":"2012","journal-title":"Med Clin North Am."},{"key":"10.1016\/j.arteri.2021.02.006_bib0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1022101417810","article-title":"Therapy of diabetes and dyslipidemia in acromegaly","volume":"5","author":"Tamburrano","year":"2002","journal-title":"Pituitary."},{"key":"10.1016\/j.arteri.2021.02.006_bib0215","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MOL.0b013e3283606845","article-title":"Alcohol and plasma triglycerides","volume":"24","author":"Klop","year":"2013","journal-title":"Curr Opin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0220","doi-asserted-by":"crossref","first-page":"F925","DOI":"10.1152\/ajprenal.1997.273.6.F925","article-title":"Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure","volume":"273","author":"Vaziri","year":"1997","journal-title":"Am J Physiol Physiol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11154-016-9402-z","article-title":"Dyslipidemia in patients with chronic kidney disease","volume":"18","author":"Hager","year":"2017","journal-title":"Rev Endocr Metab Disord."},{"key":"10.1016\/j.arteri.2021.02.006_bib0230","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/ki.1996.515","article-title":"Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure","volume":"50","author":"Vaziri","year":"1996","journal-title":"Kidney Int."},{"key":"10.1016\/j.arteri.2021.02.006_bib0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-9-5","article-title":"Impaired plasma lipid profiles in acute hepatitis","volume":"9","author":"Luo","year":"2010","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.arteri.2021.02.006_bib0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2013.10.030","article-title":"Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology","volume":"232","author":"Loria","year":"2014","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.arteri.2021.02.006_bib0245","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5152\/eurjrheum.2019.19029","article-title":"Are there any differences among psoriasis, psoriatic arthritis and rheumatoid arthritis in terms of metabolic syndrome and cardiovascular risk factors?","volume":"6","author":"Ozkul","year":"2019","journal-title":"Eur J Rheumatol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0250","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.arteri.2021.02.006_bib0255","author":"Al-Samkari","year":"2017","journal-title":"Hemophagocytic Lymphohistiocytosis"},{"key":"10.1016\/j.arteri.2021.02.006_bib0260","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamadermatol.2018.3679","article-title":"Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene","volume":"154","author":"Cabello","year":"2018","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0265","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jacl.2015.04.006","article-title":"Secondary hypertriglyceridemia in children and adolescents","volume":"9","author":"Blackett","year":"2015","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0270","series-title":"Harrison's Principles of Internal Medicine","first-page":"2889","article-title":"400 Disorders of Lipoprotein Metabolism","author":"Rader","year":"2018"},{"key":"10.1016\/j.arteri.2021.02.006_bib0275","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/clp.14.52","article-title":"Identifying pseudohypertriglyceridemia in clinical practice","volume":"9","author":"Backes","year":"2014","journal-title":"Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0280","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0889-8529(05)70033-5","article-title":"Drugs causing dyslipoproteinemia","volume":"27","author":"Donahoo","year":"1998","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.1016\/j.arteri.2021.02.006_bib0285","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jacl.2018.05.021","article-title":"Combination therapy of omega-3 fatty acids and acipimox for children with hypertriglyceridemia and acute lymphoblastic leukemia","volume":"12","author":"Salvador","year":"2018","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0290","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jacl.2018.01.003","article-title":"The prevalence and etiology of extreme hypertriglyceridemia in children: Data from a tertiary children's hospital","volume":"12","author":"Patni","year":"2018","journal-title":"J Clin Lipidol."},{"key":"10.1016\/j.arteri.2021.02.006_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/petr.12914","article-title":"Dyslipidemia after pediatric renal transplantation\u2014The impact of immunosuppressive regimens","volume":"21","author":"Habbig","year":"2017","journal-title":"Pediatr Transplant."},{"key":"10.1016\/j.arteri.2021.02.006_bib0300","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0022-2275(20)34475-8","article-title":"Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women","volume":"41","author":"Wolfe","year":"2000","journal-title":"J Lipid Res."},{"key":"10.1016\/j.arteri.2021.02.006_bib0305","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJM199110243251702","article-title":"Effects of Postmenopausal Estrogen Replacement on the Concentrations and Metabolism of Plasma Lipoproteins","volume":"325","author":"Walsh","year":"1991","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2021.02.006_bib0310","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/0026-0495(82)90231-1","article-title":"Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides","volume":"31","author":"Beil","year":"1982","journal-title":"Metabolism."},{"key":"10.1016\/j.arteri.2021.02.006_bib0315","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int J Antimicrob Agents."},{"issue":"Suppl. 18","key":"10.1016\/j.arteri.2021.02.006_bib0320","first-page":"27","article-title":"Dyslipidemia and atypical antipsychotic drugs","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916821000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:32:40Z","timestamp":1759325560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916821000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":32,"alternative-id":["S0214916821000395"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2021.02.006","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hipertrigliceridemias secundarias","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2021.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}